Accessibility Menu
BioHarvest Sciences logo

BioHarvest Sciences(NASDAQ) BHST

Market Cap$35.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-77%
5 Year-80%
1 Year-77%
1 Month+7%
$2.01
-1.94%
-0.04Today
BioHarvest Sciences last closing stock price
MetricPriceDate
Last closeUSD 2.052026-08-24
BioHarvest Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.53%USD 2.172026-08-17
1 month+6.77%USD 1.922026-07-24
3 month-47.57%USD 3.912026-05-26
Year to date-60.5%USD 5.192025-12-31
1 year-76.52%USD 8.732025-08-22
3 year-54.95%USD 4.552023-08-25
5 year-80.48%USD 10.502021-08-25
Since inception-76.71%USD 8.802020-04-23

BioHarvest Sciences Financials at a Glance

Market Cap

$35.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$35.48M

Net Income (TTM)

-$11.07M

EPS (TTM)

-$0.52

P/E Ratio

-3.91

Dividend

$0.00

Beta (Volatility)

-29.71 (Low)

Price

$2.01

Volume

25,324.042

Open

$2.02

Previous Close

$2.05

Daily Range

$2.00 - $2.06

52-Week Range

$1.82 - $12.80

Estimated Earnings Date

Nov 12, 2026

BHST News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology firm specializing in the development of nutraceuticals and pharmaceuticals. The company utilizes a proprietary botanical synthesis platform to cultivate active ingredients from plant cells, creating clinically validated therapeutic products.

Products and Services
  • VINIA, a dietary supplement derived from red grape cells
  • Contract development and manufacturing services for third parties
  • Evidence-based therapeutic products for health and wellness
Growth Outlook
  • Revenue of $8.8 million reported in Q2 2026, showing strong market demand
  • Gross profit margin of 57.5% in Q2 2026 indicates effective cost management
  • Current ratio of 2.24 suggests strong liquidity and financial health
Financial Highlights
  • Net income of -$3.7 million in Q2 2026, reflecting ongoing investment in growth
  • Cash and cash equivalents of $16.2 million as of June 30, 2026, providing operational stability
  • Operating expenses of $7.6 million in Q2 2026, indicating a focus on scaling operations
BioHarvest Sciences Inc. operates in a dynamic sector, leveraging innovative technology to create health-focused products. The company's flagship product, VINIA, has gained traction in the wellness market, contributing to its revenue growth. Recent financial results indicate a commitment to expanding operations, despite current net losses. The liquidity position remains robust, allowing for continued investment in research and development. As the company navigates its growth trajectory, it remains poised to capitalize on emerging opportunities in the biotechnology space.
AI Generated • Aug 19, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

89

CEO

Zaki Rakib, PhD

Website

www.bioharvest.com

Headquarters

Vancouver, BC V6C 2T6, CA

BHST Financials

Key Financial Metrics (TTM)

Gross Margin

58.95%

Operating Margin

-17.99%

Net Income Margin

-31.21%

Return on Equity

-58.30%

Return on Capital

-14.10%

Return on Assets

-24.84%

Earnings Yield

-25.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$35.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.33M

Volume

25.32K

Avg. Volume

49.20K

Financials (TTM)

Gross Profit

$20.91M

Operating Income

-$6.38M

EBITDA

-$7.29M

Operating Cash Flow

-$8.71M

Capital Expenditure

-$2.24M

Free Cash Flow

-$10.95M

Cash & ST Invst.

$16.22M

Total Debt

$17.55M

BioHarvest Sciences Performance Analysis

BioHarvest Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,498,000161.6%
20232023-12-31USD 12,672,000130.5%
20242024-12-31USD 25,188,00098.8%
20252025-12-31USD 34,508,00037.0%
BioHarvest Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.5%
Q42025-12-31-0.0%
Q12026-03-31-6.2%
Q22026-06-303.9%
BioHarvest Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.869.0%
20232023-12-31USD -0.937.9%
20242024-12-31USD -0.80-14.1%
20252025-12-31USD -0.60-24.2%
BioHarvest Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3041.7%
Q42025-12-3114.3%
Q12026-03-31N/A
Q22026-06-30-33.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$8.84M

+3.8%

Gross Profit

$5.08M

-0.1%

Gross Margin

57.51%

N/A

Market Cap

$35.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$399.12K

N/A

Employees

89

N/A

Net Income

-$3.72M

+8.9%

EBITDA

-$2.02M

-43.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$16.22M

+335.3%

Total Debt

$17.55M

-16.8%

Accounts Receivable

$4.18M

+69.0%

Inventory

$5.78M

+40.0%

Long Term Debt

$13.13M

-12.0%

Short Term Debt

$4.42M

-28.4%

Return on Assets

-24.84%

N/A

Return on Invested Capital

-19.40%

N/A

Free Cash Flow

-$3.33M

-56.9%

Operating Cash Flow

-$2.77M

-83.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MERCMercer International Inc.
$0.42+4.56%
BIOXBioceres Crop Solutions Corp.
$0.42+1.31%
LVROLavoro Limited
$0.13+0.00%
AVDAmerican Vanguard Corporation
$2.18+0.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$212.22+0.02%
INTCIntel
$88.95+0.02%
BITOProShares Trust - ProShares Bitcoin ETF
$10.68+0.00%
IBITiShares Bitcoin Trust
$44.81+0.00%

Questions About BHST

What is the current price of BioHarvest Sciences?

BioHarvest Sciences is trading at $2.01 per share.

What is the 52-week range for BioHarvest Sciences?

Over the past 52 weeks, BioHarvest Sciences has traded between $1.82 and $12.80.

How much debt does BioHarvest Sciences have?

As of the most recent reporting period, BioHarvest Sciences reported total debt of $17.55M.

How much cash does BioHarvest Sciences have on hand?

BioHarvest Sciences reported $16.22M in cash and cash equivalents in its most recent financial results.

What is BioHarvest Sciences’s dividend yield?

BioHarvest Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services